Phase 1 N=30 Crossover, Single Dose, Two-stage Bioequivalence Study of SCMC-Lys Salt 1.35 g Powder vs SCMC-Lys Salt 90 mg/mL Syrup
Bronchitis
Primary: Carbocysteine Plasma PK Parameters: Cmax — 7.15; 6.34 µg/mL — p=0.0482
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=114 MSB0011359C (M7824) in Participants With Metastatic or Locally Advanced Solid Tumors
Solid Tumors
Primary: Number of Participants With Dose Limiting Toxicity (DLT) — 0; 0; 1 Participants
Phase 1 N=45 A Study to Assess the Effect of AZD4041 on Respiratory Drive in Recreational Opioid Users.
Opioid Use Disorder
Primary: Number of Participants With Increased End-tidal Carbon Dioxide (EtCO2) of at Least 10 mmHg Compared to Baseline or > 50 mmHg on Day 1 — 0; 0 Participants
Phase 1 N=41 COVID-19 Vaccination Using a 2nd Generation (E1/E2B/E3-Deleted) Adenoviral Platform in Healthy South African Adults
Covid19
Primary: Number of Participants With Medically Attended Adverse Events (MAAE) — 0; 0; 0; 1 Participants
Phase 1 N=19 A Study Evaluating Relative Bioavailability of an Oral Suspension of Abrocitinib and Effect of an Acid Reducing Agent on the Bioavailability of Abrocitinib and Assessing the Taste of Abrocitinib Oral Formulations.
Healthy Volunteers
Primary: AUCinf of Abrocitinib Following the Administration of Abrocitinib Commercial Tablet, Abrocitinib Oral Suspension Formulation 1 or Famotidine Plus Abrocitinib Commerical…
Phase 1 N=24 A First-in-human Study of Multiple Doses of Topically Administered PF-07295324 and PF-07259955
Healthy
Primary: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) — 3; 1; 1; 1 Participants
Phase 1 N=12 A Study to Learn About the Tastes of Different Suspensions With the Study Medicine (PF-07923568) in Healthy Adult Participants.
Healthy
Primary: Mean Score of Sensory Attributes Based on Palatability Assessment Questionnaire at 1 Minute Post-dose on Day 1 — 80.3; 49.4; 54.0; 48.5 Units on a scale
Phase 1 N=20 Study to Assess the Effect of the New HFA-152a Propellant on Mucociliary Clearance
Mucociliary Clearance
Primary: Mucociliary Clearance Rate -- Right Whole Lung -- Percent Particle Retention at 2 Hours (PPR2) on Day 8 — 0.94; -0.42 percent of particle retention — p=0.442
Phase 1 N=11 A Trial to Evaluate the Effect of C21 on Endothelial Dysfunction in Subjects With Type 2 Diabetes
Type2diabetes · Endothelial Dysfunction
Primary: Pharmacodynamic Effect — 1.787; 1.911 score on a scale — p=0.1925
Phase 1 N=12 Safety, Tolerability and Pharmacokinetics Study of STP1 in a Subgroup of Patients With Autism Spectrum Disorder (ASD)
Autism Spectrum Disorder
Primary: Safety and Tolerability — 6; 3; 3 Participants
Phase 1 N=39 Navtemadlin and Radiation Therapy in Treating Patients With Soft Tissue Sarcoma
Resectable Soft Tissue Sarcoma · Soft Tissue Sarcoma
Primary: Maximum Tolerated Dose (MTD) / Recommended Phase 2 Dosage for Each Cohort — 5; NA times per week of 125mg PO
Phase 1 N=18 Bioavailability of Bosutinib Administered as Capsule Contents Mixed With Applesauce or Yogurt Relative to Intact Capsules Under Fed Condition
Healthy Participants
Primary: Area Under the Concentration-time Curve From Time 0 to Infinity (AUCinf) for Bosutinib — 3312; 3205; 3161 nanogram•hour per milliliter (ng•hr/mL)
Phase 1 N=66 Marijuana in Combination With Opioids in Palliative and Hospice Patients
Pain
Primary: Primary Reduction of Pain — 2.55; 1.40 units on a scale from 0 to 10
Phase 1 N=23 Phase Ib Study of BKM120 With Cisplatin and XRT in High Risk Locally Advanced Squamous Cell Cancer of Head and Neck
Carcinoma, Squamous Cell of Head and Neck · HPV Positive Oropharyngeal Squamous Cell Carcinoma · Hypopharyngeal Cancer
Primary: Maximum Tolerated Dose of Cisplatin — 30 mg/m2
Phase 1 N=20 A First-in-human Study of Single Doses of PF-07328948 Which is Given to Healthy Adult Participants
Healthy
Primary: Number of Participants Reporting Treatment-Emergent Adverse Events (TEAEs) — 3; 1; 3; 2 Participants